Abstract
Aim:
Comparative proteomics provide a powerful approach in screening for alterations in protein levels and post-translational modifications that are associated with tumors. In the present study, we aimed to identify candidate biomarkers to distinguish osteosarcoma (OS) cells from normal osteoblastic cells.
Methods:
We employed 3 OS cell lines (U2OS, IOR/OS9, and SaOS-2), and used the SV40-immortalized normal osteoblastic cell line (hFOB1.19) as the control. The differential protein levels in OS and osteoblastic cells were identified using 2-D gel electrophoresis followed by matrix-assisted laser desorption/ionization-time of flight mass spectrometry analyses. Two proteins of interest, the levels of which were significantly increased in OS cells, were further characterized by Western blot analyses.
Results:
Twenty-six proteins were identified, the expression level of which was either significantly increased or decreased in the OS cells as compared to the control cells. The expression level of the activator of 90 kDa shock protein ATPase homolog 1 (AHA1), was enhanced 12.4-, 24.1-, and 23.8-fold in SaOS-2, IOR/OS9, and U2OS cells, respectively, and the level of the stomatin-like protein 2 (SLP-2) was increased by 10.4- and 7.8-fold in IOR/OS9 and U2OS cells, respectively, as compared to normal osteoblastic cells. Those observations were confirmed by Western blot analyses.
Conclusion:
A differential proteomic analysis was successfully used to identify AHA1 and SLP-2 that were significantly overproduced in OS cells as compared to normal osteoblastic cells, suggesting that those proteins among others may be effective biomarker candidates for the identification of OS cells.
Similar content being viewed by others
Article PDF
References
Sandberg AA, Bridge JA . Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet, 2003; 145: 1–30.
Marina N, Gebhardt M, Teot L, Gorlick R . Biology and therapeutic advances for pediatric osteosarcoma. Oncologist, 2004; 9: 422–41.
Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocals. J Clin Oncol, 2002; 20: 776–90.
Zeindl-Eberhar E, Haraida S, Liebmann S, Jungblut PR, Mayer D, Jager G, et al. Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology, 2004; 39: 540–49.
Li C, Chen Z, Xiao Z, Wu X, Zhan X, Zhang X, et al. Comparative proteomics analysis of human lung squamous carcinoma. Biochem Biophys Res Commun, 2003; 309: 253–60.
Johansson B, Pourian MR, Chuan YC, Byman I, Bergh A, Pang ST, et al. Proteomic comparison of prostate cancer cell lines LNCaP-FGC and LNCaP-r reveals heat shock protein 60 as a marker for prostate malignancy. Prostate, 2006; 66: 1235–44.
An HJ, Kim DS, Park YK, Kim SK, Choi YP, Kang K, et al. Comparative proteomics of ovarian epithelial tumors. J Proteome Res, 2006; 5: 1082–90.
Afjehi-Sadat L, Shin JH, Felizardo M, Lee K, Slavc I, Lubec G . Detection of hypothetical proteins in 10 individual human tumor cell lines. Biochim Biophys Acta, 2005; 1747: 67–80.
Wolf M, El-Rifai W, Tarkkanen M, Kononen J, Serra M, Eriksen EF, et al. Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet Cytogenet, 2000; 123: 128–32.
Atiye J, Wolf M, Kaur S, Monni O, Bohling T, Kivioja A, et al. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer, 2005; 42: 158–63.
Spreafico A, Frediani B, Capperucci C, Chellini F, Paffetti A, D'Ambrosio C, et al. A proteomic study on human osteoblastic cells proliferation and differentiation. Proteomics, 2006; 6: 3520–32.
Zhang L, Ding F, Cao W, Liu Z, Yu Z, Wu Y, et al. Stomatin-like protein 2 is overexpressed in cancer and involved in regulating cell growth and cell adhesion in human esophageal squamous cell carcinoma. Clin Cancer Res, 2006; 12: 1639–46.
Lynch M, Chen L, Ravitz MJ, Mehtani S, Korenblat K, Pazin MJ, et al. HnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation. Mol Cell Biol, 2005; 25: 6436–53.
Mazurek S, Boschek CB, Hugo F, Eigenbrodt E . Pyruvate kinase type M2 and its role in tumor growth and spreading. Semin Cancer Biol, 2005; 15: 300–8.
Panaretou B, Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, et al. AT P binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 1998; 17: 4829–36.
Obermann WM, Sondermann H, Russo AA, Pavletich N P, Hartl FU . In vivo function of Hsp90 is dependent on ATP binding and AT P hydrolysis. J Cell Biol, 1998; 16: 901–10.
Lotz GP, Lin H, Harst A, Obermann WM . Aha1 binds to the middle domain of Hsp90, contributes to client protein activation, and stimulates the ATPase activity of the molecular chaperone. J Biol Chem, 2003; 278: 17 228–35.
Mayer MP, Nikolay R, Bukau B . Aha, another regulator for Hsp90 chaperones. Mol Cell, 2002; 10: 1255–6.
Stiligardi G, Panaretou B, Meyer P, Singh S, Woolfson DN, Pearl LH, et al. Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37. J Biol Chem, 2002; 277: 20 151–9.
Panaretou B, Siligardi G, Meyer P, Maloney A, Sullivan JK, Singh S, et al. Activation of the ATPase activity of Hsp90 by the stress-regulated cochaperone Aha1. Mol Cell, 2002; 10: 1307–18.
Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature, 2003; 425: 407–10.
Neckers L . Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med, 2002; 8: S55–61.
Wang Y, Morrow JS . Identification and characterization of human SLP-2, a novel homologue of stomatin (band 7.2b) present in erythrocytes and other tissues. J Biol Chem, 2000; 275: 8062–71.
John J P, Anrather D, Pollak A, Lubec G . Mass spectrometrical verification of stomatin-like protein 2 (SLP-2) primary structure. Proteins, 2006; 64: 543–51.
Owczarek CM, Treutlein HR, Portbury KJ, Gulluyan LM, Kola I, Hertzog PJ . A novel member of the STOMATIN/EPB72/mec-2 family, stomatin-like 2 (STOML2), is ubiquitously expressed and localizes to HSA chromosome 9p13.1. Cytogenet Cell Genet, 2001; 92: 196–203.
Hasina R, Hulett K, Bicciato S, Di Bello C, Petruzzelli GJ, Lingen MW . Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res, 2003; 63: 555–9.
Whitbread AK, Masoumi A, Tetlow N, Schmuck E, Coggan M, Board PG . Characterization of the omega class of glutathione transferases. Methods Enzymol, 2005; 401: 78–99.
Dulhunty A, Gage P, Curtis S, Chelvanayagam G, Board P . The glutathione transferase structural family includes a nuclear chloride channel and a ryanodine receptor calcium release channel modulator. J Biol Chem, 2001; 276: 3319–23.
Marahatta SB, Punyarit P, Bhudisawasdi V, Paupairoj A, Wongkham S, Petmitr S . Polymorphism of glutathione S-trans-ferase omega gene and risk of cancer. Cancer Lett, 2006; 236: 276–81.
Peene I, Meheus L, Keyser SD, De-Keyser S, Humbel R, Veys EM, et al. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis, 2002; 61: 929–33.
Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, et al. Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci, 2006; 97: 380–6.
Roers A, Hochkeppel HK, Horisberger MA, Hovanessian A, Haller O . MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis, 1994; 169: 807–13.
Willipinski-Stapelfeldt B, Riethdorf S, Assmann V, Woelfle U, Rau T, Sauter G, et al. Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res, 2005; 11: 8006–14.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by Guangzhou Municipal Key Project Foundation (No 2005Z3E0101) and the Science and Technology Development Foundation of Guangdong Province (No 2005B34001002 and 2003C34102).
Rights and permissions
About this article
Cite this article
Guo, Qc., Shen, Jn., Jin, S. et al. Comparative proteomic analysis of human osteosarcoma and SV40-immortalized normal osteoblastic cell lines. Acta Pharmacol Sin 28, 850–858 (2007). https://doi.org/10.1111/j.1745-7254.2007.00603.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00603.x
Keywords
This article is cited by
-
AHA1 regulates cell migration and invasion via the EMT pathway in colorectal adenocarcinomas
Scientific Reports (2021)
-
Comparative analysis of the surface exposed proteome of two canine osteosarcoma cell lines and normal canine osteoblasts
BMC Veterinary Research (2013)
-
Surface proteomic analysis of osteosarcoma identifies EPHA2 as receptor for targeted drug delivery
British Journal of Cancer (2013)
-
Plasma membrane proteomic analysis of human osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma
Tumor Biology (2011)
-
Comparative proteomic analysis of plasma membrane proteins between human osteosarcoma and normal osteoblastic cell lines
BMC Cancer (2010)